Newron Pharmaceuticals SpA (NWRN) - Cash Flow Conversion Efficiency

Latest as of June 2025: 21.083x

Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) has a cash flow conversion efficiency ratio of 21.083x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF33.35 Million ≈ $42.17 Million USD) by net assets (CHF1.58 Million ≈ $2.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Newron Pharmaceuticals SpA - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Newron Pharmaceuticals SpA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NWRN total liabilities for a breakdown of total debt and financial obligations.

Newron Pharmaceuticals SpA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Newron Pharmaceuticals SpA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Elitegroup Computer Systems Co Ltd
TW:2331
0.005x
Tourism Finance Corporation of India Limited
NSE:TFCILTD
-0.041x
Southern States Bancshares Inc
NASDAQ:SSBK
0.033x
Barings Corporate Investors
NYSE:MCI
0.013x
Guiyang Xintian Pharmaceutical Co Ltd
SHE:002873
0.039x
Fleetpartners Group Ltd
AU:FPR
-0.084x
Tupy S.A
SA:TUPY3
0.101x
Volcon Inc
NASDAQ:VLCN
-0.265x

Annual Cash Flow Conversion Efficiency for Newron Pharmaceuticals SpA (2005–2024)

The table below shows the annual cash flow conversion efficiency of Newron Pharmaceuticals SpA from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Newron Pharmaceuticals SpA stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CHF1.46 Million
≈ $1.84 Million
CHF-17.61 Million
≈ $-22.27 Million
-12.081x -3663.28%
2023-12-31 CHF-29.91 Million
≈ $-37.81 Million
CHF-10.14 Million
≈ $-12.82 Million
0.339x -57.12%
2022-12-31 CHF-14.03 Million
≈ $-17.74 Million
CHF-11.09 Million
≈ $-14.02 Million
0.791x +121.46%
2021-12-31 CHF3.11 Million
≈ $3.93 Million
CHF-11.45 Million
≈ $-14.47 Million
-3.684x -307.54%
2020-12-31 CHF17.25 Million
≈ $21.80 Million
CHF-15.59 Million
≈ $-19.71 Million
-0.904x -51.35%
2019-12-31 CHF36.80 Million
≈ $46.52 Million
CHF-21.98 Million
≈ $-27.78 Million
-0.597x -105.27%
2018-12-31 CHF54.84 Million
≈ $69.33 Million
CHF-15.95 Million
≈ $-20.17 Million
-0.291x -134.45%
2017-12-31 CHF67.72 Million
≈ $85.62 Million
CHF-8.40 Million
≈ $-10.62 Million
-0.124x +68.48%
2016-12-31 CHF49.75 Million
≈ $62.89 Million
CHF-19.58 Million
≈ $-24.76 Million
-0.394x -13.58%
2015-12-31 CHF37.11 Million
≈ $46.92 Million
CHF-12.86 Million
≈ $-16.26 Million
-0.347x -1.43%
2014-12-31 CHF29.26 Million
≈ $36.99 Million
CHF-10.00 Million
≈ $-12.64 Million
-0.342x +32.56%
2013-12-31 CHF21.09 Million
≈ $26.66 Million
CHF-10.69 Million
≈ $-13.51 Million
-0.507x -340.15%
2012-12-31 CHF27.61 Million
≈ $34.90 Million
CHF5.83 Million
≈ $7.36 Million
0.211x +128.11%
2011-12-31 CHF6.58 Million
≈ $8.33 Million
CHF-4.94 Million
≈ $-6.25 Million
-0.750x +52.17%
2010-12-31 CHF12.19 Million
≈ $15.41 Million
CHF-19.13 Million
≈ $-24.18 Million
-1.569x -99.27%
2009-12-31 CHF29.28 Million
≈ $37.02 Million
CHF-23.06 Million
≈ $-29.15 Million
-0.787x -80.96%
2008-12-31 CHF45.81 Million
≈ $57.92 Million
CHF-19.93 Million
≈ $-25.20 Million
-0.435x -80.11%
2007-12-31 CHF57.40 Million
≈ $72.57 Million
CHF-13.87 Million
≈ $-17.53 Million
-0.242x -70.22%
2006-12-31 CHF67.86 Million
≈ $85.79 Million
CHF-9.63 Million
≈ $-12.17 Million
-0.142x +83.14%
2005-12-31 CHF17.02 Million
≈ $21.52 Million
CHF-14.33 Million
≈ $-18.12 Million
-0.842x --

About Newron Pharmaceuticals SpA

SW:NWRN Switzerland Biotechnology
Market Cap
$360.88 Million
CHF285.44 Million CHF
Market Cap Rank
#14173 Global
#149 in Switzerland
Share Price
CHF14.30
Change (1 day)
-3.38%
52-Week Range
CHF6.66 - CHF30.40
All Time High
CHF30.40
About

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more